Karen M MacDonald (Karen MacDonald)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Topics

Allergic Rhinitis

Tyrosine Kinase

Small Cell Lung Cancer

Systematic Review

Top Venues

Journal of medical economics

Expert review of clinical immunology

Future oncology (London, England)

Clinical ophthalmology (Auckland, N.Z.)

This page only lists publications with an associated author ORCID identifier.

Publications

Ivo Abraham, Matthias Calamia, Nimer S Alkhatib, Marc Pondel, Karen M MacDonald
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer. Journal of medical economics (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics (2024)
Ivo Abraham, Matthias Calamia, Nimer S Alkhatib, Marc Pondel, Karen M MacDonald
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer. Journal of medical economics 27 (sup3) (2024)
Karen M MacDonald, Marc Pondel, Ivo Abraham
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)
Rebecca M Thiede, Mohammad Fazel, Karen M MacDonald, Ivo Abraham
Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Expert opinion on pharmacotherapy 23 (14) (2022)
Ali McBride, Karen M MacDonald, Adolfo Fuentes-Alburo, Ivo Abraham
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of medical economics 24 (1) (2021)
Dina Hamarneh, Nimer S Alkhatib, Kris Denhaerynck, Stefaan Vancayzeele, Heidi Brié, Karen M MacDonald, Ivo Abraham
Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. Current medical research and opinion 37 (3) (2021)
Ali McBride, Neda Alrawashdh, Karen M MacDonald, Ivo Abraham
Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future oncology (London, England) (2021)
Ivo Abraham, Uchenna Onyekwere, Baris Deniz, Donald Moran, Marc Chioda, Karen M MacDonald, Huan Huang
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of medical economics (2021)
Karen M MacDonald, Neda Alrawashdh, Ali McBride, Ivo Abraham
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future oncology (London, England) 17 (33) (2021)
Ali McBride, Karen M MacDonald, Adolfo Fuentes-Alburo, Ivo Abraham
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Journal of medical economics 24 (1) (2021)
Anita M Leys, Eva Ramboer, Mérédis Favreau, Kris Denhaerynck, Karen M MacDonald, Ivo Abraham, Heidi Brié
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study. Clinical ophthalmology (Auckland, N.Z.) 14 (2020)
Elisabeth H van Aken, Mérédis Favreau, Eva Ramboer, Kris Denhaerynck, Karen M MacDonald, Ivo Abraham, Heidi Brié
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study). Clinical ophthalmology (Auckland, N.Z.) 14 (2020)
Nimer S Alkhatib, Diana Sun, Kris Denhaerynck, Dina Hamarneh, Yoleen Van Camp, Lorenzo Villa, Heidi Brié, Stefaan Vancayzeele, Karen M MacDonald, Ivo Abraham
Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients. Current medical research and opinion 37 (1) (2020)
Kenneth M Faulkner, Karen M MacDonald, Ivo Abraham, Abdulaziz Alhossan, Christopher S Lee
'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert review of clinical immunology 17 (1) (2020)
Karen M MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S Lee, Ivo Abraham
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert review of clinical immunology 15 (5) (2019)
Noha Ashy, Thanh-Nga Nguyen, Kris Denhaerynck, Mahdi Gharaibeh, Abdulaziz Alhossan, Stefaan Vancayzeele, Heidi Brié, Ann Aerts, Karen M MacDonald, Ivo Abraham
Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. International journal of chronic diseases 2017 (2017)